var data={"title":"Influenza virus vaccine (inactivated): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Influenza virus vaccine (inactivated): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/55282?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=influenza-virus-vaccine-inactivated-patient-drug-information\" class=\"drug drug_patient\">see &quot;Influenza virus vaccine (inactivated): Patient drug information&quot;</a> and <a href=\"topic.htm?path=influenza-virus-vaccine-inactivated-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Influenza virus vaccine (inactivated): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50338608\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Influenza Update</span>\n      <span class=\"collapsible-date\">January 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Centers for Disease Control and Prevention (CDC) is reporting a significant increase in influenza activity over recent weeks, with influenza A(H3N2) viruses predominating. Past A(H3N2) virus-predominant influenza seasons have been associated with more hospitalizations and deaths in persons 65 years of age and older, as well as in young children, compared to other age groups. Influenza vaccine effectiveness has also been generally lower against A (H3N2) viruses than against influenza A (H1N1) pdm09 or influenza B viruses. Last influenza season, vaccine effectiveness against circulating A (H3N2) viruses was estimated to be 32% in the US and is expected to be similar this season if the same A (H3N2) viruses continue to predominate. Influenza activity was high in the Southern Hemisphere in 2017 and preliminary data from Australia suggest overall vaccine effectiveness of 33% but only 10% against A (H3N2) viruses, making the use of antiviral medications for treatment of influenza, in addition to preventive vaccination, even more important.</p>\n        <p style=\"text-indent:0em;\">The CDC has also issued a health advisory stating that all hospitalized patients, patients with severe, complicated, or progressive illness (including outpatients), and all high-risk patients (including pediatric patients younger than 2 years; adults 65 years and older; patients with certain chronic illnesses or neurologic or neurodevelopmental conditions; immunosuppressed patients; women who are pregnant or postpartum (within 2 weeks of delivery); patients younger than 19 years of age receiving long term aspirin therapy; American Indians/Alaska Natives; patients with BMI of 40 or more; and residents of nursing homes or other chronic-care facilities) with suspected or confirmed influenza should be treated as soon as possible with a neuraminidase inhibitor antiviral (eg, oseltamivir, peramivir, zanamivir). Adamantanes (eg, amantadine, rimantadine) are not currently recommended for treatment or prophylaxis of influenza A because of high levels of resistance. Antivirals for influenza work best when initiated within 48 hours of illness onset; however, clinical benefit has been observed even when treatment is initiated later in some patients.</p>\n        <p style=\"text-indent:0em;\">Further information is available at <a target=\"_blank\" href=\"https://emergency.cdc.gov/han/han00409.asp&amp;token=/XpciKoGXD/NBcI56myByIrj6XDzXmi2bFm6I7VYATsTAoPzpN4M+ut5dGKrD6OM&amp;TOPIC_ID=9055\" target=\"_blank\">https://emergency.cdc.gov/han/han00409.asp</a> and <a target=\"_blank\" href=\"https://www.cdc.gov/flu/weekly/summary.htm&amp;token=R4Uiw8/bmPVaqNHRDqpXLOtzxb+vTZhOOrHrvoZzklFBp7r1xCTELF4KBDcLrJouICpPDwRTIgOkmOCDxEXvOQ==&amp;TOPIC_ID=9055\" target=\"_blank\">https://www.cdc.gov/flu/weekly/summary.htm</a>.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Influenza New Recommendations</span>\n      <span class=\"collapsible-date\">August 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Centers for Disease Control and Prevention (CDC) is recommending that core requirements for influenza immunization remain the same for the 2017&ndash;2018 flu season. The Advisory Committee on Immunization Practices (ACIP) is also recommending that any licensed, recommended, and age-appropriate trivalent or quadrivalent inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV) be allowed for pregnant women. The previous recommendation specified use of IIV for pregnant women. ACIP reiterated that the quadrivalent live attenuated influenza nasal spray vaccine (LAIV4) should not be used in any setting during the upcoming flu season. Afluria (IIV3) is now indicated for people 5 years and older (previously 9 years and older). The influenza vaccine strains approved for the 2017&ndash;2018 season in the US are:</p>\n        <ul>\n          <li>\n            <p style=\"text-indent:0em;\">Trivalent vaccines:</p>\n            <ul>\n              <li>\n                <p style=\"text-indent:0em;\">A/Michigan/45/2015 (H1N1) pdm09&ndash;like virus (updated)</p></li>\n              <li>\n                <p style=\"text-indent:0em;\">A/Hong Kong/4801/2014 (H3N2)&ndash;like virus</p></li>\n              <li>\n                <p style=\"text-indent:0em;\">B/Brisbane/60/2008&ndash;like virus (Victoria lineage)</p></li></ul></li>\n          <li>\n            <p style=\"text-indent:0em;\">Quadrivalent vaccines:</p>\n            <ul>\n              <li>\n                <p style=\"text-indent:0em;\">The 3 trivalent vaccines, plus B/Phuket/3073/2013&ndash;like virus (Yamagata lineage)</p></li></ul></li></ul></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560252\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Afluria;</li>\n      <li>Afluria Quadrivalent;</li>\n      <li>Fluad;</li>\n      <li>Fluarix Quadrivalent;</li>\n      <li>Flucelvax Quadrivalent;</li>\n      <li>Flucelvax [DSC];</li>\n      <li>FluLaval Quadrivalent;</li>\n      <li>Fluvirin;</li>\n      <li>Fluzone High-Dose;</li>\n      <li>Fluzone Intradermal Quadrivalent;</li>\n      <li>Fluzone Quadrivalent;</li>\n      <li>Fluzone [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560327\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Agriflu;</li>\n      <li>Fluad;</li>\n      <li>Fluad Pediatric;</li>\n      <li>Flulaval Tetra;</li>\n      <li>Fluviral;</li>\n      <li>Fluzone High-Dose;</li>\n      <li>Fluzone Quadrivalent;</li>\n      <li>Influvac</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560255\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Viral)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600936\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">It is important to note that influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available (and, if possible, by the end of October) and prior to onset of influenza activity in the community. However, vaccination should continue throughout the influenza season as long as vaccine is available. The CDC does not recommend revaccination later in the season for those persons who have already been fully vaccinated. Unless noted, the ACIP does not have a preference for any given inactivated influenza vaccine (IIV) formulation when used within their specified age indications (CDC/ACIP [Grohskopf 2017)].</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Immunization:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Afluria, Afluria Quadrivalent:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &le;64 years: IM or via PharmaJet Stratis Needle-Free Injection System: 0.5 mL per dose as a single dose (1 dose per season)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &gt;64 years: IM: 0.5 mL per dose as a single dose (1 dose per season)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Fluarix Quadrivalent, Flucelvax Quadrivalent, FluLaval Quadrivalent, Fluvirin, Fluzone Quadrivalent:</i> IM: 0.5 mL/dose (1 dose per season)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Fluzone Intradermal Quadrivalent:</i> Adults 18 to 64 years: Intradermal: 0.1 mL/dose (1 dose per season)</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">Canadian labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Agriflu, FluLaval Tetra, Fluviral, Fluzone Quadrivalent:</i> IM: 0.5 mL/dose (1 dose per season)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Influvac:</i> IM, SubQ: 0.5 mL/dose (1 per season)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560266\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=influenza-virus-vaccine-inactivated-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Influenza virus vaccine (inactivated): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">It is important to note that influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available (and, if possible, by the end of October) and prior to onset of influenza activity in the community. However, vaccination should continue throughout the influenza season as long as vaccine is available. Unless noted, the ACIP does not have a preference for any given inactivated influenza vaccine (IIV) formulation when used within their specified age indications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Immunization:</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Afluria and Afluria Quadrivalent:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 5 to 8 years: 0.5 mL/dose (1 or 2 doses per season; see <b>&quot;Note&quot;</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;9 years of age and Adolescents: 0.5 mL per dose as a single dose (1 dose per season).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Fluarix Quadrivalent, FluLaval Quadrivalent:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children 6 months to 8 years: 0.5 mL/dose (1 or 2 doses per season; see <b>&quot;Note&quot;</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;9 years of age and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Flucelvax Quadrivalent, Fluvirin:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 8 years: 0.5 mL/dose (1 or 2 doses per season; see &quot;<b>Note</b>&quot;)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;9 years of age and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Fluzone Quadrivalent:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children 6 to 35 months: 0.25 mL/dose (1 or 2 doses per season; see <b>&quot;Note&quot;</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 3 to 8 years: 0.5 mL/dose (1 or 2 doses per season; see <b>&quot;Note&quot;</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;9 years of age and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> Infants and children 6 months to &lt;9 years of age who received at least 2 doses of trivalent or quadrivalent influenza vaccine prior to July 1, 2017 need only 1 dose of the 2017 to 2018 seasonal influenza vaccine. The 2 doses need not have been received during the same season or consecutive seasons. All other children &lt;9 years of age (including those whose vaccination status cannot be determined) should receive 2 doses separated by &ge;4 weeks in order to achieve satisfactory antibody response (CDC/ACIP [Grohskopf 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Canadian labeling: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Agriflu, Fluzone Quadrivalent:</i> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children 6 to 35 months: Manufacturer labeling: 0.25 mL/dose; NACI recommendation: 0.5 mL/dose (NACI 2017) (1 dose per season); a second dose should be administered 4 weeks after the first in previously unvaccinated patients</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 3 to 8 years: 0.5 mL/dose (1 dose per season); a second dose should be administered 4 weeks after the first in previously unvaccinated patients</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;9 years of age and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Fluad Pediatric:</i> IM: Infants and Children 6 months to &lt; 2 years of age: 0.25 mL/dose (1 dose per season); a second dose should be administered 4 weeks after the first in previously unvaccinated patients and in patients who were vaccinated for the first time last season and only one dose was received.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>FluLaval Tetra, Fluviral:</i> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;6 months and Children &lt;9 years of age: 0.5 mL/dose (1 dose per season); a second dose should be administered 4 weeks after the first in previously unvaccinated patients</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;9 years of age and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Influvac:</i> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;3 years of age and Adolescents: 0.5 mL/dose (1 dose per season); a second dose should be administered 4 weeks after the first in previously unvaccinated children</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600937\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">It is important to note that influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available (and, if possible, by October) and prior to onset of influenza activity in the community. However, vaccination should continue throughout the influenza season as long as vaccine is available. The high-dose inactivated influenza vaccine (IIV), Fluzone High-Dose, contains 60 mcg of each vaccine antigen per 0.5 mL dose compared to 15 mcg of each vaccine antigen per 0.5 mL dose. The high-dose IIV formulation was shown to elicit a higher antibody response and may provide better protection against influenza illness compared to standard dose IIV3 formulations. However, the ACIP does not have a preference for any given IIV formulation in older adults when used within their specified age indications (CDC/ACIP [Grohskopf 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Immunization:</b> Adults &ge;65 years of age:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Afluria, Afluria Quadrivalent, Fluad, Fluarix Quadrivalent, Flucelvax Quadrivalent, FluLaval Quadrivalent, Fluvirin, Fluzone High-Dose, Fluzone Quadrivalent:</i> IM: 0.5 mL/dose (1 dose per season).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Canadian labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Agriflu, Fluad, FluLaval Tetra, Fluviral, Fluzone Quadrivalent, Fluzone High-Dose: </i>IM: 0.5 mL/dose (1 dose per season)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Influvac:</i> IM, SubQ: 0.5 mL/dose (1 per season)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897886\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897887\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600938\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension, Intramuscular:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Afluria: (5 mL) [contains egg white (egg protein), neomycin sulfate, polymyxin b, thimerosal]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Afluria Quadrivalent: (5 mL) [contains egg white (egg protein), neomycin sulfate, polymyxin b, thimerosal]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flucelvax Quadrivalent: (5 mL) [contains polysorbate 80, thimerosal]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">FluLaval Quadrivalent: (5 mL) [contains egg white (egg protein), formaldehyde solution, polysorbate 80, thimerosal]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluvirin: (5 mL) [contains egg white (egg protein), neomycin, polymyxin, thimerosal]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluzone: (5 mL [DSC]) [contains egg white (egg protein), formaldehyde solution, gelatin (pork), thimerosal]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluzone Quadrivalent: (5 mL) [contains egg white (egg protein), formaldehyde solution, thimerosal]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension, Intramuscular [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluzone Quadrivalent: (0.5 mL) [contains egg white (egg protein), formaldehyde solution]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension Pen-injector, Intradermal [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluzone Intradermal Quadrivalent: 9 mcg/strain (0.1 mL) [contains egg white (egg protein), formaldehyde solution]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension Prefilled Syringe, Intramuscular [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Afluria: (0.5 mL) [contains egg white (egg protein), neomycin sulfate, polymyxin b]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Afluria Quadrivalent: (0.5 mL) [contains egg white (egg protein), neomycin sulfate, polymyxin b]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluad: (0.5 mL) [contains egg white (egg protein), formaldehyde solution, neomycin, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluarix Quadrivalent: (0.5 mL) [contains egg white (egg protein), formaldehyde solution, gentamicin, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flucelvax: (0.5 mL [DSC]) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flucelvax Quadrivalent: (0.5 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">FluLaval Quadrivalent: (0.5 mL) [contains egg white (egg protein), polysorbate 80, formaldehyde solution]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluvirin: (0.5 mL) [contains egg white (egg protein), neomycin, polymyxin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluzone High-Dose: (0.5 mL) [contains egg white (egg protein), formaldehyde solution]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluzone Quadrivalent: (0.25 mL, 0.5 mL) [contains egg white (egg protein), formaldehyde solution]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560328\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13703758\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Agriflu: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, neomycin (may have trace amounts), kanamycin (may have trace amounts), formaldehyde, polysorbate 80, thimerosal]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">FluLaval Tetra: (5 mL) [contains chicken egg protein, formaldehyde solution, polysorbate 80, thimerosal]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluviral: Hemagglutinin 45 mcg/0.5 mL (5 mL) [contains chicken egg protein, formaldehyde, polysorbate 80, thimerosal]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluzone Quadrivalent: Hemagglutinin 45 mcg/0.5 mL (5 mL) [contains chicken egg protein, formaldehyde, thimerosal]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Agriflu: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, neomycin (may have trace amounts), kanamycin (may have trace amounts), formaldehyde, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluad: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, formaldehyde, neomycin (may have trace amounts), kanamycin (may have trace amounts), polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluad Pediatric: Hemagglutinin 22.5 mcg/0.25 mL (0.25 mL) [contains chicken egg protein, formaldehyde, neomycin (may have trace amounts), kanamycin (may have trace amounts), polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluzone Quadrivalent: Hemagglutinin 45 mcg/0.5 mL (0.25 ml, 0.5 mL) [contains chicken egg protein, formaldehyde]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Influvac: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, formaldehyde, gentamicin (may have trace amounts), polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734123\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the U.S, the appropriate CDC-approved  Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/flu.html&amp;token=i/T/o2k6OLX6THAlHOY5IA5jGKSiJvxwNnmNCErfziwUYKRutfar2OJecb3NZBuk69UGq4WB70REX6D0Wkg7rA==&amp;TOPIC_ID=9055\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/flu.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560343\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>Fluzone Intradermal Quadrivalent:</i> For intradermal administration, preferably into the skin over the deltoid muscle only. Gently shake gently prior to use. Hold system using the thumb and middle finger (do not place fingers on windows). Insert needle perpendicular to the skin; inject using index finger to push on plunger. Do not aspirate.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>Afluria, Afluria Quadrivalent, Fluad, Fluarix Quadrivalent, Flucelvax Quadrivalent, FluLaval Quadrivalent, Fluvirin, Fluzone High-Dose, Fluzone Quadrivalent, Agriflu [Canadian product], Fluad, Fluad Pediatric [Canadian product], FluLaval Tetra [Canadian product], Fluviral [Canadian product]:</i> For IM administration only. Suspensions should be shaken well prior to use. Inspect for particulate matter and discoloration prior to administration. Some manufacturers recommend avoiding use if visible particles or discoloration are present in the suspension after shaking. See manufacturer labeling for specific recommendations. Adults and older children should be vaccinated in the deltoid muscle. Infants and young children should be vaccinated in the anterolateral aspect of the thigh. Children &ge;1 years with adequate deltoid muscle mass may be vaccinated in the deltoid (ACIP [Kroger 2017]). Do not inject into the gluteal region or areas where there may be a major nerve trunk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      Afluria and Afluria Quadrivalent via PharmaJet Stratis Needle-free Injection System: For IM administration in adults 18 to 64 years of age only. For detailed instructions on preparation and administration of a dose, refer to the information available online at www.pharmajet.com.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>Influvac [Canadian product]:</i> May be administered by IM or deep subcutaneous injection. Shake well prior to use. Allow to warm to room temperature prior to use.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Unless otherwise indicated in product labeling, jet injectors should <b>not</b> be used to administer inactivated influenza vaccines. Currently, <i>Afluria </i>and<i> Afluria Quadrivalent </i>are the only influenza vaccines licensed in the United States with data about use with a jet-injector device.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">If a pediatric vaccine (0.25 mL) is inadvertently administered to an adult, an additional 0.25 mL should be administered to provide the full adult dose (0.5 mL). If the error is discovered after the patient has left, an adult dose should be given as soon as the patient can return. If an adult vaccine (0.5 mL) is inadvertently given to a child, no action needs to be taken (CDC/ACIP [Grohskopf 2017]). <i>Agriflu [Canadian product]:</i> If 0.25 mL dose is to be given, discard half the contained syringe volume prior to administration.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560341\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Influenza disease prevention:</b> Active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine in the following persons:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; 6 months and older (Fluarix Quadrivalent, FluLaval Quadrivalent, Fluzone Quadrivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; 4 years and older (Flucelvax Quadrivalent, Fluvirin)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; 5 years and older (Afluria and Afluria Quadrivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; 18 through 64 years of age (Fluzone Intradermal Quadrivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; 65 years and older (Fluad, Fluzone High-Dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; 6 months to &lt;2 years (Fluad Pediatric)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; 6 months and older (Agriflu, FluLaval Tetra, Fluviral, Fluzone Quadrivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; 3 years and older (Influvac)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; 65 years and older (Fluad, Fluzone High-Dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine annual vaccination with the seasonal influenza vaccine for all persons &ge;6 months of age who do not otherwise have contraindications to the vaccine (ACIP [Grohskopf 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The ACIP recommends use of any age and risk factor appropriate product and does not have a preferential recommendation for use of the trivalent inactivated influenza vaccine (IIV<sub>3</sub>) or the quadrivalent inactivated influenza vaccine (IIV<sub>4</sub>). In addition to the IIV products, other alternative products are available for certain patient populations: Persons 18 years and older may receive vaccination with the recombinant influenza vaccine (RIV). Although live attenuated influenza vaccine (LAIV<sub>4</sub>) is FDA-approved for healthy nonpregnant persons aged 2 to 49 years, the ACIP recommends that LAIV<sub>4</sub> should not be used for any population for the 2017-18 season due to concerns regarding low effectiveness during the 2013-14 and 2015-16 seasons (ACIP [Grohskopf 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The Canadian National Advisory Committee on Immunization (NACI) recommends annual vaccination with seasonal influenza vaccine for all persons &ge;6 months who do not otherwise have contraindications to the vaccine. Healthy, nonpregnant persons aged 2 to 59 years may receive vaccination with the seasonal live, attenuated influenza vaccine (LAIV) (nasal spray). When readily available and no contraindications exist, LAIV (nasal spray) may be used in healthy persons 2 to 17 years of age. LAIV is not recommended in patients with severe asthma, active wheezing, wheezing requiring medical attention in the 7 days prior to vaccination, adults with chronic health conditions, and children and adults who are immunocompromised. For persons 6 months to 17 years of age, use of quadrivalent inactivated influenza vaccine (QIV) or trivalent inactivated influenza vaccine (TIV) if QIV is not available, is recommended (NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">When vaccine supply is limited, target groups for vaccination (those at higher risk of complications from influenza infection and their close contacts) include the following (CDC/ACIP [Grohskopf 2017]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infants and children 6 to 59 months of age</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons &ge;50 years of age</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infants, children, and adolescents (6 months to 18 years of age) who are receiving long-term aspirin or salicylate therapy, and therefore, may be at risk for developing Reye syndrome after influenza</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Women who are or will be pregnant during the influenza season</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients with chronic pulmonary disorders (including asthma) or cardiovascular systems disorders (except hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons who have immunosuppression (including immunosuppression caused by medications or HIV)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Residents of nursing homes and other long-term care facilities</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; American Indians/Alaska Natives</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Morbidly obese (BMI &ge;40)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Health care personnel</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Household contacts (including children) and caregivers of neonates, infants, and children &lt;5 years (particularly children &lt;6 months) and adults &ge;50 years</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Household contacts (including children) and caregivers of persons with medical conditions which put them at high risk of severe complications from influenza infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560326\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fluarix may be confused with Flarex</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">FluMist may be confused with flumazenil</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Influenza virus vaccine may be confused with perflutren lipid microspheres</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Influenza virus vaccine may be confused with tetanus toxoid and tuberculin products. IIV may be confused with PPD. Medication errors have occurred when tuberculin skin tests (PPD) have been inadvertently administered instead of tetanus toxoid products and influenza virus vaccine. These products are refrigerated and often stored in close proximity to each other.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Influenza virus vaccine may be confused with insulin. Medication errors have occurred when insulin was inadvertently administered instead of influenza virus vaccine. These products are refrigerated and may be stored in close proximity to each other.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fluarix [US, Canada, and multiple international markets] may be confused with Flarex brand name for fluorometholone [US and multiple international markets] and Fluorex brand name for fluoride [France]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560258\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. Adverse reactions in adults &ge;65 years of age may be greater using the high-dose vaccine, but are typically mild and transient.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest tightness, hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, drowsiness, fatigue, headache, irritability, malaise, migraine, shivering</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, ecchymoses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, diarrhea, gastroenteritis, nausea, sore throat, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection, varicella</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reactions (including bruising, erythema, hematoma at injection site, induration, inflammation, itching at injection site, pain, rash, soreness, swelling at injection site, tenderness at injection site)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia (may start within 6 to 12 hours and last 1 to 2 days; incidence generally equal to placebo in adults; occurs more frequently than placebo in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, cough, dyspnea, nasal congestion, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngolaryngeal pain, rhinitis, rhinorrhea, upper respiratory tract infection, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal gait, anaphylactic shock, anaphylaxis, angioedema, arthritis, asthma, Bell's palsy, brachial plexopathy, brain disease, bronchospasm, cellulitis, chest pain, confusion, constriction of the pharynx, cranial nerve palsy, dizziness, dysphagia, eye pain, facial paralysis, febrile seizures, flu-like symptoms, flushing, Guillain-Barre syndrome, Henoch-Sch&ouml;nlein purpura (immunoglobulin A vasculitis), hot flash, hypersensitivity reaction (including oculorespiratory syndrome, an acute, self-limited reaction with ocular and respiratory symptoms) (CDC/ACIP [Grohskopf 2013]), hypoesthesia, hypokinesia, insomnia, laryngitis, limb pain, lymphadenopathy, maculopapular rash, microscopic polyangiitis, myasthenia, myelitis (including encephalomyelitis), neuralgia, neuritis (including brachial), ocular hyperemia, optic neuritis, optic neuropathy, pallor, paralysis (including limb), paresthesia, pharyngeal edema, photophobia, presyncope, pruritus, seizure, serum sickness, skin rash, Stevens-Johnson syndrome, swelling of injected limb (lasting &gt;1 week), syncope, thrombocytopenia, transverse myelitis, tremor, urticaria, vasculitis (including transient renal involvement), vasodilatation, vesicobullous rash, voice disorder, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9560342\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe allergic reaction (eg, anaphylaxis) to a previous influenza vaccination or to any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional manufacturer contraindications for Afluria, Afluria Quadrivalent, Fluad, Fluarix Quadrivalent, FluLaval Quadrivalent, Fluvirin, Fluzone High-Dose, Fluzone Intradermal Quadrivalent, Fluzone Quadrivalent: History of severe allergic reaction (eg, anaphylaxis) to egg protein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional manufacturer contraindications for Canadian products: Agriflu, Fluad, Fluad Pediatric, FluLaval Tetra, Fluviral, Fluzone High-Dose, Fluzone Quadrivalent, Influvac: Hypersensitivity to egg protein.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note</b>: Both ACIP and NACI do not consider egg allergy a contraindication to influenza vaccination (CDC/ACIP [Grohskopf 2017]; NACI 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600929\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oculorespiratory syndrome: Oculorespiratory syndrome (ORS) is an acute, self-limiting reaction to IIV with one or more of the following symptoms appearing within 2 to 24 hours after the dose: Chest tightness, cough, difficulty breathing, facial swelling, red eyes, sore throat, or wheezing. Symptoms resolve within 48 hours of onset. The cause of ORS has not been established, but studies have suggested that it is not IgE-mediated. However, because ORS symptoms may be similar to those of an IgE-mediated hypersensitivity reaction, health care providers unsure of etiology of symptoms should seek advice from an allergist/immunologist when determining whether a patient may be revaccinated in subsequent seasons (CDC/ACIP [Grohskopf 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Febrile seizures: Postmarketing reports of increased incidence of fever and febrile seizures in children &lt;5 years of age has been observed with the use of the 2010 Southern Hemisphere formulation of the Afluria vaccine. Febrile events have also been reported in children 5 to &lt;9 years of age. Based on information from the CDC, an increased rate of febrile seizures has been reported in young children 6 to 23 months who received vaccination with inactivated influenza vaccine (IIV) and the 13-valent pneumococcal conjugate vaccine (PCV13) 7-valent pneumococcal conjugate vaccine (PCV7), or DTaP-containing vaccines. However, due to the risks associated with delaying either vaccine, administering them at separate visits or deviating from the recommended vaccine schedule is not currently recommended (CDC/ACIP [Grohskopf 2017]). Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Guillain-Barr&eacute; syndrome: Use with caution in patients with history of Guillain-Barr&eacute; syndrome (GBS); patients with history of GBS have a greater likelihood of developing GBS than those without. As a precaution, the ACIP recommends that patients with a history of GBS and who are at low risk for severe influenza complications, and patients known to have experienced GBS within 6 weeks following previous vaccination should generally not be vaccinated (consider influenza antiviral chemoprophylaxis in these patients). The benefits of vaccination may outweigh the potential risks in persons with a history of GBS who are also at high risk for complications of influenza (CDC/ACIP [Grohskopf 2017]). Recent studies of patients who received the trivalent inactivated influenza vaccine or the monovalent H1N1 influenza vaccine have shown the risk of GBS is lower with vaccination than with influenza infection (Baxter 2013; Greene 2013; Kwong 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV: Antigenic response may not be adequate in HIV-infected persons with CD4 cells &lt;100/mm<sup>3</sup> and viral copies of HIV type 1 &gt;30,000/mL, and a second dose does not improve immune response in these persons (CDC/ACIP [Grohskopf 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurologic disorders: Some Canadian product labeling recommends delaying therapy in patients with active neurologic disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP, as well as the Canadian National Advisory Committee on Immunization (NACI), recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible; however, vaccination should not be deferred because a specific brand is unavailable; (ACIP [Kroger 2017]; NACI 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroid]); may have a reduced response to vaccination. Inactivated vaccine (IIV or RIV) is preferred over live virus vaccine for household members, healthcare workers and others coming in close contact with severely-immunosuppressed persons requiring care in a protected environment (ACIP [Kroger 2017]; CDC/ACIP [Grohskopf 2017]). Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Antibody responses may be lower and decline faster in older adults &ge;65 years of age compared to younger adults, especially by 6 months postvaccination; however, deferral to later in the season may result in missed vaccination opportunities or early season infection (CDC/ACIP [Grohskopf 2017]). Fluzone High-Dose contains 4 times the amount of each influenza antigen compared to other inactivated virus vaccines and was shown to elicit a higher antibody response and may provide better protection against influenza illness in older adults compared to standard dose IIV3 formulations (DiazGranados 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oncology patients: Seasonal influenza immunization (with inactivated vaccine) is recommended for all patients receiving chemotherapy for malignancy, and for all family and household contacts (Flowers 2013). Lifelong seasonal influenza immunization (with inactivated vaccine) is also recommended for hematopoietic cell transplant candidates and recipients; vaccination of family members and close or household contacts is strongly recommended during each flu season and continuing annually as long the recipient is immunocompromised, even if beyond 24 months after transplant (CIBMTR [Tomblyn 2009]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chicken egg protein: Most products are manufactured with chicken egg protein (expressed as ovalbumin content when content is disclosed on prescribing information). The ovalbumin content may vary from season to season and lot to lot of vaccine. Allergy to eggs must be distinguished from allergy to the vaccine. Recommendations are available from the ACIP and NACI regarding influenza vaccination to persons who report egg allergies; however, ACIP states a prior severe allergic reaction to influenza vaccine, regardless of the component suspected, is a contraindication to vaccination. Per ACIP, patients with a history of egg allergy who have experienced only hives following egg exposure should receive influenza vaccine if otherwise appropriate. Patients with a history of egg allergy other than hives (eg, angioedema, respiratory distress) should receive influenza vaccine if otherwise appropriate and administered in an inpatient or outpatient medical setting with health care supervision able to recognize and manage severe allergic conditions (CDC/ACIP [Grohskopf 2017]). However, AAP, American Academy of Allergy, Asthma, and Immunology (AAAAI)/American College of Allergy, Asthma, and Immunology (ACAAI), and NACI state that patients may receive vaccination regardless of severity of egg allergy and no special precautions are required (AAP 2017; Greenhawt 2018; NACI 2017). Flucelvax Quadrivalent (ccIIV<sub>4</sub>) is an inactivated influenza vaccine manufactured using cell-culture technology and provides an alternative to vaccines cultured with chicken-egg protein but should not be considered egg free (CDC/ACIP [Grohskopf 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gentamicin: Some products are manufactured with gentamicin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kanamycin: Some products are manufactured with kanamycin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Packaging may contain natural latex rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neomycin: Some products are manufactured with neomycin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polymyxin: Some products are manufactured with polymyxin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thimerosal: Some products contain thimerosal; hypersensitivity reactions may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Immunization Schedules (ACIP [Kim 2017]; CDC/ACIP [Robinson 2017]). Specific recommendations for use of this vaccine in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions are available from the IDSA (Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Previous season vaccines: Influenza vaccines from previous seasons must not be used (CDC/ACIP [Grohskopf 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299519\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221011\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9055&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Influenza Virus Vaccine (Inactivated) may increase the serum concentration of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pneumococcal Conjugate Vaccine (13-Valent): Influenza Virus Vaccine (Inactivated) may diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent). Pneumococcal Conjugate Vaccine (13-Valent) may diminish the therapeutic effect of Influenza Virus Vaccine (Inactivated). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600925\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B/C (manufacturer specific) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600926\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Inactivated influenza vaccine has not been shown to cause fetal harm when given to pregnant women, although information related to use in the first trimester is limited. Maternal influenza infection hypothetically may be associated with adverse fetal events. Even so, CDC recommends its use. Following maternal immunization with the inactivated influenza virus vaccine, vaccine-specific antibodies are observed in the newborn (CDC/ACIP [Grohskopf 2017]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women are at an increased risk of complications from influenza infection. The inactivated influenza vaccine provides protective concentrations of antibodies in pregnant women and does not increase the risk for adverse maternal outcomes (CDC/ACIP [Grohskopf 2017]). Influenza vaccination with any licensed, recommended, age-appropriate vaccine is recommended for all women who are or will become pregnant during the influenza season and who do not otherwise have contraindications to the vaccine (CDC/ACIP [Grohskopf 2017]). Pregnant women should observe the same precautions as nonpregnant women to reduce the risk of exposure to influenza and other respiratory infections (CDC/HHS 2017). When vaccine supply is limited, focus on delivering the vaccine should be given to women who are pregnant or will be pregnant during the flu season, as well as mothers of newborns and contacts or caregivers of children &lt;5 years of age (CDC/ACIP [Grohskopf 2017]). Vaccination may be done at any time during pregnancy (ACOG 2014).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women exposed to FluLaval Quadrivalent, or Fluarix Quadrivalent vaccine during pregnancy or their health care provider may contact the GlaxoSmithKline registry at 888-452-9622.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women exposed to Afluria Quadrivalent or Flucelvax Quadrivalent vaccine during pregnancy may contact the Seqirus registry at 855-358-8966 or via email at us.medicalinformation@seqirus.com.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers may enroll women exposed to Fluzone Intradermal Quadrivalent or Fluzone Quadrivalent during pregnancy in the Sanofi Pasteur vaccination registry at 800-822-2463.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600928\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if inactivated influenza vaccine is present in breast milk. Anti-influenza IgA antibodies can be detected in breast milk following maternal vaccination with the trivalent IIV vaccine (Schlaudecker 2013). Administration does not affect the safety of breastfeeding for the mother or the infant (ACIP [Kroger 2017]). When vaccine supply is limited, focus on delivering the vaccine should be given to women who are pregnant or who may become pregnant during the flu season, as well as mothers of newborns and contacts or caregivers of children &lt;5 years (CDC/ACIP [Grohskopf 2017]). Breastfeeding infants should be vaccinated according to the recommended schedules (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13315042\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]; CDC/ACIP [Grohskopf 2016]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600931\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Promotes immunity to seasonal influenza virus by inducing specific antibody production. Each year the formulation is standardized according to the US Public Health Service. Preparations from previous seasons must not be used. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600933\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Most adults have antibody protection within 2 weeks of vaccination (CDC/ACIP [Grohskopf 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: &ge;6 to 8 months when vaccine is antigenically similar to circulating virus (CDC/ACIP [Grohskopf 2016]); response may be diminished in persons &ge;65 years of age and limited evidence suggests titers may decline significantly 6 months following vaccination in this population (CDC/ACIP [Grohskopf 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570492\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Fluzone Quadrivalent Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mL (0.5 mL): $21.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Pen-injector</b> (Fluzone Quadrivalent Intradermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9 mcg/strain (0.1 mL): $21.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Prefilled Syringe</b> (Afluria Preservative Free Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mL (0.5 mL): $20.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Prefilled Syringe</b> (Afluria Quadrivalent Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mL (0.5 mL): $20.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Prefilled Syringe</b> (Fluad Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mL (0.5 mL): $52.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Prefilled Syringe</b> (Fluarix Quadrivalent Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mL (0.5 mL): $20.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Prefilled Syringe</b> (Flucelvax Quadrivalent Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mL (0.5 mL): $25.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Prefilled Syringe</b> (Flulaval Quadrivalent Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mL (0.5 mL): $20.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Prefilled Syringe</b> (Fluvirin Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mL (0.5 mL): $20.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Prefilled Syringe</b> (Fluzone High-Dose Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mL (0.5 mL): $51.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Prefilled Syringe</b> (Fluzone Quadrivalent Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mL (0.25 mL): $22.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mL (0.5 mL): $21.41</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27657868\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Afluria (HR);</li>\n      <li>Flivirin (BB);</li>\n      <li>Fluarix (AE, AR, AT, BG, CH, CL, CO, CR, CY, CZ, DK, DO, EE, ES, FI, FR, GR, GT, HN, HR, ID, IE, IL, IN, IS, IT, KW, LT, MT, MX, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, SA, SE, SI, SK, SV, TH, UY, VE, VN);</li>\n      <li>Fluarix Tetra (AU, CZ, ES, GB, HK, IL, MY, SK, TH);</li>\n      <li>Fluenz Tetra (GB);</li>\n      <li>Fluquadri (SG);</li>\n      <li>Fluvax (AU, HK, NZ, SG);</li>\n      <li>Fluvirin (ZA);</li>\n      <li>Flyuaryks (UA);</li>\n      <li>Influgen (IN);</li>\n      <li>Influvac (AE, AR, AU, BG, CH, CL, CY, CZ, DE, DK, EE, FI, FR, GR, HR, IE, IL, KW, LT, LV, MT, MX, NL, NO, NZ, PL, QA, SA, SE, SI, SK);</li>\n      <li>Intanza (AT, BE, CZ, DE, DK, EE, ES, GB, HR, LT, MT, NL, NZ, PL, PT, SG, TH, UA);</li>\n      <li>Optaflu (AT, MT, SK);</li>\n      <li>Vepacel (IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Afluria (influenza vaccine) [prescribing information]. Summit, NJ: Seqirus; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Afluria Quadrivalent (influenza vaccine) [prescribing information]. Summit, NJ: Seqirus; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Agriflu (influenza vaccine) [product monograph]. Ottawa, Ontario, Canada: Seqirus Canada Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2017 &ndash; 2018 [published correction appears in <i>Pediatrics</i>. 2018;141(1):e20173535]. <i>Pediatrics</i>. 2017;140(4):e20172550. doi: 10.1542/peds.2017-2550.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/28870977/pubmed\" target=\"_blank\" id=\"28870977\">28870977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Committee opinion no. 608: influenza vaccination during pregnancy. <i>Obstet Gynecol</i>. 2014;124(3):648-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/25162283/pubmed\" target=\"_blank\" id=\"25162283\">25162283</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Auffret M, B&eacute;n&eacute; J, Gautier S, et al. Pharmacovigilance monitoring of a cohort of pregnant women vaccinated against influenza A(H1N1) variant virus in the Nord-Pas de Calais region of northern France. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2013;170(1):114-118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/23810001/pubmed\" target=\"_blank\" id=\"23810001\">23810001</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baxter R, Bakshi N, Fireman B, et al. Lack of association of Guillain-Barre syndrome with vaccinations. <i>Clin Infect Dis</i>. 2013;57(2):197-204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/23580737/pubmed\" target=\"_blank\" id=\"23580737\">23580737</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bischoff AL, F&oslash;lsgaard NV, Carson CG, et al. Altered response to A(H1N1)pnd09 vaccination in pregnant women: a single blinded randomized controlled trial. <i>PLoS One</i>. 2013;8(4):e56700.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/23637733/pubmed\" target=\"_blank\" id=\"23637733\">23637733</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carcione D, Blyth CC, Richmond PC, et al. Safety surveillance of influenza vaccine in pregnant women. <i>Aust N Z J Obstet Gynaecol</i>. 2013;53(1):98-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/23406000/pubmed\" target=\"_blank\" id=\"23406000\">23406000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Pregnant Women &amp; Influenza (Flu). Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service. <a href=\"http://www.cdc.gov/flu/protect/vaccine/pregnant.htm\" target=\"_blank\">http://www.cdc.gov/flu/protect/vaccine/pregnant.htm</a>. Updated August 30, 2017. Accessed September 5, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Update on Febrile Seizures in Children Following Vaccination With Influenza Vaccines and Pneumococcal Vaccines. Updated October 2011. Available at <a href=\"http://www.cdc.gov/vaccinesafety/Concerns/FebrileSeizures.html\" target=\"_blank\">http://www.cdc.gov/vaccinesafety/Concerns/FebrileSeizures.html</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults.<i> N Engl J Med.</i> 2014;371(7):635-645. doi: 10.1056/NEJMoa1315727.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/25119609/pubmed\" target=\"_blank\" id=\"25119609\">25119609</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Englund JA, Mbawuike IN, Hammill H, Holleman MC, Baxter BD, Glezen WP. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. <i>J Infect Dis</i>. 1993;168(3):647-656.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/8354906/pubmed\" target=\"_blank\" id=\"8354906\">8354906</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2013;31(6):794-810.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/23319691/pubmed\" target=\"_blank\" id=\"23319691\">23319691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluad (influenza vaccine) [prescribing information]. Summit, NJ: Seqirus Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluad Pediatric and Fluad (influenza vaccine) [product monograph]. Dorval, Quebec, Canada: Seqirus; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluarix Quadrivalent (influenza vaccine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flucelvax Quadrivalent (influenza vaccine) [prescribing information]. Summit, NJ: Seqirus Inc.; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FluLaval Quadrivalent (influenza vaccine) [prescribing information]. Research Triangle Park, NC; GlaxoSmithKline; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FluLaval Tetra (influenza vaccine) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluviral (influenza vaccine) [product monograph]. Quebec, Quebec, Canada: ID Biomedical Corporation of Quebec; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluvirin (influenza vaccine) [prescribing information]. Summit, NJ: Seqirus; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluzone High-Dose (influenza vaccine) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; July 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/25121712/pubmed\" target=\"_blank\" id=\"25121712\">25121712</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluzone High-Dose (influenza vaccine) [product monograph]. Toronto, Ontario, Canada: Sanofi Pasteur Ltd; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluzone Intradermal Quadrivalent (influenza vaccine) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluzone Quadrivalent (influenza vaccine) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluzone Quadrivalent (influenza vaccine) [product monograph]. Toronto, Ontario, Canada: Sanofi Pasteur Ltd; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greene SK, Rett MD, Vellozzi C, et al. Guillain-Barr&eacute; Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011. <i>PLoS One</i>. 2013;8(6):e67185.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/23840621/pubmed\" target=\"_blank\" id=\"23840621\">23840621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenhawt M, Turner PJ, Kelso JM. Administration of influenza vaccines to egg allergic recipients: A practice parameter update 2017. <i>Ann Allergy Asthma Immunol</i>. 2018;120(1):49-52. doi: 10.1016/j.anai.2017.10.020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/29273128/pubmed\" target=\"_blank\" id=\"29273128\">29273128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2016-17 Influenza Season. <i>MMWR Morb Mortal Wkly Rep</i>. 2016;65(5):1-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/27560619/pubmed\" target=\"_blank\" id=\"27560619\">27560619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2017-18 Influenza Season. <i>MMWR Recomm Rep</i>. 2017;66(2):1-20. doi: 10.15585/mmwr.rr6602a1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/28841201/pubmed\" target=\"_blank\" id=\"28841201\">28841201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Influvac (influenza vaccine) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma; May 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/27560619/pubmed\" target=\"_blank\" id=\"27560619\">27560619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, et.al.; Advisory Committee on Immunization Practices (ACIP), ACIP Adult Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older&mdash;United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017; 66(5):136-138. doi: 10.15585/mmwr.mm6605e2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kwong JC, Vasa PP, Campetelli MA, et al. Risk of Guillain-Barr&eacute; syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. <i>Lancet Infecti Dis</i>. 2013;13(9):769-776.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/23810252/pubmed\" target=\"_blank\" id=\"23810252\">23810252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Advisory Committee on Immunization (NACI); Committee to Advise on Tropical Medicine and Travel (CATMAT). Canadian Immunization Guide. Public Health Agency of Canada website. http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php. Published 2012. Updated March 2014. Accessed September 17, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Advisory Committee on Immunization (NACI). Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2017&ndash;2018. Public Health Agency of Canada website. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2017-2018.html#a5. Accessed August 28, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al. Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials. <i>Lancet</i>. 2009;374(9698):1339-1350.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rasmussen SA, Jamieson DJ, and Bresee JS, &quot;Pandemic Influenza and Pregnant Women,&quot; <i>Emerg Infect Dis</i>. 2008;14(1):95-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/18258087/pubmed\" target=\"_blank\" id=\"18258087\">18258087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Romero JR, Kempe A, et.al.; Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schlaudecker EP, Steinhoff MC, Omer SB, et al. IgA and neutralizing antibodies to influenza a virus in human milk: a randomized trial of antenatal influenza immunization. <i>PLoS One</i>. 2013;8(8):e70867.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/23967126/pubmed\" target=\"_blank\" id=\"23967126\">23967126</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steinhoff MC, Omer SB, Roy E, et al. Influenza Immunization in Pregnancy--Antibody Responses in Mothers and Infants. <i>N Engl J Med</i>. 2010;362(17):1644-1646.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/20427817/pubmed\" target=\"_blank\" id=\"20427817\">20427817</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction in <i>Biol Blood Marrow Transplant</i>. 2010;16(2):294]. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zaman K, Roy E, Arifeen SE, et al. Effectiveness of Maternal Influenza Immunization in Mothers and Infants,&rdquo; <i>N Engl J Med</i>. 2008;9(15):1555-1564.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/18799552/pubmed\" target=\"_blank\" id=\"18799552\">18799552</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuccotti G, Pogliani L, Pariani E, Amendola A, Zanetti A. Transplacental antibody transfer following maternal immunization with a pandemic 2009 influenza A(H1N1) MF59-adjuvanted vaccine. <i>JAMA</i>. 2010;304(21):2360-2361.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/influenza-virus-vaccine-inactivated-drug-information/abstract-text/21119083/pubmed\" target=\"_blank\" id=\"21119083\">21119083</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9055 Version 204.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50338608\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9560252\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9560327\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9560255\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9600936\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F9560266\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9600937\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15897886\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15897887\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9600938\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9560328\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F13703758\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734123\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9560343\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9560341\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9560326\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9560258\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9560342\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9600929\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299519\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221011\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9600925\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9600926\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9600928\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13315042\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9600931\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9600933\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570492\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F27657868\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9055|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=influenza-virus-vaccine-inactivated-patient-drug-information\" class=\"drug drug_patient\">Influenza virus vaccine (inactivated): Patient drug information</a></li><li><a href=\"topic.htm?path=influenza-virus-vaccine-inactivated-pediatric-drug-information\" class=\"drug drug_pediatric\">Influenza virus vaccine (inactivated): Pediatric drug information</a></li></ul></div></div>","javascript":null}